Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma., PMID:40523447
Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study., PMID:40475774
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC., PMID:40177869
[Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]., PMID:40159024
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma., PMID:40011100
Hans's algorithm and MYD88L265P mutation may affect prognosis of primary central nervous system B-cell lymphoma., PMID:39880607
CD20 and CD19 promote proliferation driven by the IgM-TLR9-L265P MyD88 complex., PMID:39868594
Epstein-Barr virus BALF0/1 subverts the Caveolin and ERAD pathways to target B cell receptor complexes for degradation., PMID:39847318
[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma]., PMID:39743255
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)., PMID:39711167
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen., PMID:39694704
TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma., PMID:39691999
Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation., PMID:39660959
Primary seminal vesicle diffuse large B-cell lymphoma: a case report and review of the literatures., PMID:39539541
High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma : Identification of an MCD-like Subtype., PMID:39483112
Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma., PMID:39428323
[Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review]., PMID:39414613
[Efficacy and safety analysis of the OR-CHOP regimen for the treatment of MCD subtype diffuse large B cell lymphoma in the real-world setting]., PMID:39414605
Immunophenotypic properties association of CLL and ALL patient cells by flow cytometry analysis., PMID:39397873
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma., PMID:39228298
Expanding the Clinical Phenotype with CD79A Mutation and Refractory Helicobacter Bilis Infection., PMID:39215847
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Deep mutational scanning reveals transmembrane features governing surface expression of the B cell antigen receptor., PMID:39108267
Control of germinal center B cell survival and IgE production by an adaptor molecule containing PH and SH2 domains, Aps/Sh2b2., PMID:39090233
The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma., PMID:39063920
Method for B Cell Receptor Enrichment in Malignant B Cells., PMID:39001403
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)., PMID:38983914
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation., PMID:38968152
Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System., PMID:38925823
[Clinicopathological features and prognosis analysis of bone marrow biopsy involvement in 95 cases with mantle cell lymphoma]., PMID:38825910
Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?, PMID:38813707
Fluoxetine Successfully Treats Intracranial Enterovirus E18 Infection in a Patient with CD79a Deficiency Arising from Segmental Uniparental Disomy of Chromosome 19., PMID:38805163
Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2., PMID:38775302
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN., PMID:38741123
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma., PMID:38683128
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes., PMID:38643457
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma., PMID:38630892
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study., PMID:38622879
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma., PMID:38519055
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut /CD79Bmut diffuse large B-cell lymphoma., PMID:38457222
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma., PMID:38411628
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL., PMID:38310754
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates., PMID:38265691
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b., PMID:38232613
B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells., PMID:38203179
Diagnostic methods for primary vitreoretinal lymphoma: A systematic review., PMID:38163550
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial., PMID:38072960
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas., PMID:38007239
For research use only. Not for human or drug use.
